Last reviewed · How we verify
Sufentanil, Hydromorphone
Sufentanil and Hydromorphone are marketed opioid analgesics developed by the University of Erlangen-Nürnberg Medical School, with a key composition patent expiring in 2028. The drugs benefit from a well-established mechanism and a strong track record in pain management, positioning them as reliable options in the opioid market. The primary risk is the impending patent expiry, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | Sufentanil, Hydromorphone |
|---|---|
| Sponsor | University of Erlangen-Nürnberg Medical School |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement) (PHASE4)
- Observational Study on the Incorporation of Opioids and Their Metabolites Into Hair of Pediatric Patients
- Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery (NA)
- Non-analgesic Effects Produced by Equipotent Analgesic Doses of Sufentanil, Hydromorphone, and Oxycodone (PHASE4)
- Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia (PHASE2)
- Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment (PHASE4)
- Effect of Epidural Hydromorphone Combined With Ropivacaine in Labor Analgesia (PHASE2)
- Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sufentanil, Hydromorphone CI brief — competitive landscape report
- Sufentanil, Hydromorphone updates RSS · CI watch RSS
- University of Erlangen-Nürnberg Medical School portfolio CI